Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

SMRF vs. SBIO: which is better?

Bottom line

SMRF vs SBIO: the short answer

SMRF (ALPS Nautilus SMR, Nuclear & Technology ETF) and SBIO (ALPS Medical Breakthroughs ETF) are both etfs.

Updated Nov 19, 2026

SMRF vs SBIO side by side

SMRFSBIO
TypeETFETF
Fund familyAlps Nautilus Smr Nuclear & TechnologyAlps
CategoryTechnology SectorHealth Care Sector
Expense ratio—0.5%
Annual cost per $10k—$50
10-yr cost on $10k (prospectus)—$628
Max front loadNoneNone
12b-1 fee——
1-yr return—+54.2%
5-yr return (annualized)—+0.7%
10-yr return (annualized)—+5.7%
Best quarter—+33.9%
Worst quarter—−30.8%
Net assets (fund)—$161.8M
Number of holdings—89
Portfolio turnover—58%
Returns as of—Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Holdings overlap

SMRF and SBIO share none of their top holdings.

SMRF top 10

    SBIO top 10

    1. Alkermes Plc — 4.48%
    2. Kymera Therapeutics Inc — 4.23%
    3. Celcuity Inc — 3.92%
    4. Mirum Pharmaceuticals Inc — 3.90%
    5. Spyre Therapeutics Inc — 3.68%
    6. Cg Oncology Inc — 3.35%
    7. Apogee Therapeutics Inc — 2.93%
    8. Xenon Pharmaceuticals Inc — 2.90%
    9. Travere Therapeutics Inc — 2.77%
    10. Dianthus Therapeutics Inc — 2.64%

    FAQ

    What is the difference between SMRF and SBIO?
    SMRF (ALPS Nautilus SMR, Nuclear & Technology ETF) and SBIO (ALPS Medical Breakthroughs ETF) are both etfs.
    Should I own both SMRF and SBIO?
    Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

    Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.